Trial Outcomes & Findings for A Novel Device for the Management of ADHD (NCT NCT05777785)

NCT ID: NCT05777785

Last Updated: 2025-03-25

Results Overview

The Adult ADHD Self-Report Scale (ASRS) is a self-report instrument that comprises eighteen items that correspond with the DSM-V-TR criteria for ADHD. Subjects are asked to rate 18 symptom items using a 5-point Likert scale ranging from 0 ('Never') to 4 ('Very Often'). Total scores range from 0 to 72, based on the sum of all 18 questions. Higher scores mean more symptoms and higher ADHD's impairments. Lower values represent better outcomes. The ASRS has two subscales that can be used to identify ADHD subtypes - Inattentiveness and Hyperactivity/Impulsivity. Each subscale contains 9 questions.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

108 participants

Primary outcome timeframe

Baseline, 2 months

Results posted on

2025-03-25

Participant Flow

108 partcipants met the inclusion criteria. Two participants failed to comply with the personalization process due to difficulty staying awake or using a cell phone during the test, resulting in 106 participants receiving the intervention.

Participant milestones

Participant milestones
Measure
Active
VIZO Glasses- personalized VIZO Glasses: Eyeglasses with personalized peripheral retinal stimuli. Participants were instructed to wear the glasses throughout the day for two months.
Overall Study
STARTED
106
Overall Study
COMPLETED
100
Overall Study
NOT COMPLETED
6

Reasons for withdrawal

Reasons for withdrawal
Measure
Active
VIZO Glasses- personalized VIZO Glasses: Eyeglasses with personalized peripheral retinal stimuli. Participants were instructed to wear the glasses throughout the day for two months.
Overall Study
Withdrawal by Subject
5
Overall Study
Lost to Follow-up
1

Baseline Characteristics

Race and Ethnicity were not collected from any participant.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Active
n=97 Participants
VIZO Glasses- personalized VIZO Glasses: Eyeglasses with personalized peripheral retinal stimuli. Participants were instructed to wear the glasses throughout the day for two months.
Age, Continuous
26.51 years
STANDARD_DEVIATION 4.59 • n=97 Participants
Sex: Female, Male
Female
51 Participants
n=97 Participants
Sex: Female, Male
Male
46 Participants
n=97 Participants
Adult ADHD Self-Report Scale (ASRS) - Total Score
39.76 units on a scale
STANDARD_DEVIATION 12.10 • n=97 Participants
Adult ADHD Self-Report Scale (ASRS) - Inattentiveness Subscale
21.2 units on a scale
STANDARD_DEVIATION 6.68 • n=97 Participants
Adult ADHD Self-Report Scale (ASRS) - Hyperactivity/Impulsivity subscale
18.56 units on a scale
STANDARD_DEVIATION 6.64 • n=97 Participants

PRIMARY outcome

Timeframe: Baseline, 2 months

Population: Two participants did not complete the questionnaire.

The Adult ADHD Self-Report Scale (ASRS) is a self-report instrument that comprises eighteen items that correspond with the DSM-V-TR criteria for ADHD. Subjects are asked to rate 18 symptom items using a 5-point Likert scale ranging from 0 ('Never') to 4 ('Very Often'). Total scores range from 0 to 72, based on the sum of all 18 questions. Higher scores mean more symptoms and higher ADHD's impairments. Lower values represent better outcomes. The ASRS has two subscales that can be used to identify ADHD subtypes - Inattentiveness and Hyperactivity/Impulsivity. Each subscale contains 9 questions.

Outcome measures

Outcome measures
Measure
Active
n=95 Participants
VIZO Glasses- personalized VIZO Glasses: Eyeglasses with personalized peripheral retinal stimuli. Participants were instructed to wear the glasses throughout the day for two months.
Adult ADHD Self-Report Scale (ASRS) - Total Score at Baseline and 2 Months Follow up
Baseline
39.76 score on a scale
Standard Error 1.24
Adult ADHD Self-Report Scale (ASRS) - Total Score at Baseline and 2 Months Follow up
End of study
38.27 score on a scale
Standard Error 1.31

PRIMARY outcome

Timeframe: Baseline, 2 months

Population: Two participants did not complete the questionnaire.

The inattentiveness sub-scale of the ASRS measures difficulties with focusing on details, organisation, remembering appointments, making careless mistakes, and concentration. It includes 9 symptom items using a 5-point Likert scale ranging from 0 ('Never') to 4 ('Very Often'). Total scores range from 0 to 36, based on the sum of all questions. Higher scores mean more symptoms and higher inattentiveness' impairments.

Outcome measures

Outcome measures
Measure
Active
n=95 Participants
VIZO Glasses- personalized VIZO Glasses: Eyeglasses with personalized peripheral retinal stimuli. Participants were instructed to wear the glasses throughout the day for two months.
Adult ADHD Self-Report Scale (ASRS) - Inattentiveness Subscale Score at Baseline and 2 Months Follow up
Baseline
21.20 score on a scale
Standard Error 0.69
Adult ADHD Self-Report Scale (ASRS) - Inattentiveness Subscale Score at Baseline and 2 Months Follow up
End of study
20.22 score on a scale
Standard Error 0.72

SECONDARY outcome

Timeframe: 2 months

Population: Nine participants did not participate in the clinicial interview.

Based on an interview with the participant, the clinician rates the total improvement on a 7 point scale as follows: 1=very much improved since the initiation of treatment; 2=much improved; 3=minimally improved; 4=no change from baseline (the initiation of treatment); 5=minimally worse; 6= much worse; 7=very much worse since the initiation of treatment.

Outcome measures

Outcome measures
Measure
Active
n=88 Participants
VIZO Glasses- personalized VIZO Glasses: Eyeglasses with personalized peripheral retinal stimuli. Participants were instructed to wear the glasses throughout the day for two months.
Clinical Global Impression-Improvement (CGI-I) - Rate at 2 Months Follow up
CGI-I score of "1", "2" or "3"
77 Participants
Clinical Global Impression-Improvement (CGI-I) - Rate at 2 Months Follow up
CGI-I score of "4" or higher
11 Participants

SECONDARY outcome

Timeframe: Baseline, 2 months

Population: Four participants did not complete the CPT.

Conners' Continuous Performance Test-3 (CPT-3) is an objective test of attention and impulsivity that has been validated in individuals aged 8 years and older. d-prime (d') is a measure of how well the respondent discriminates nontargets (i.e., the letter X) from targets (i.e., all other letters). This variable is also a signal detection statistic that measures the difference between the signal (targets) and noise (non-targets) distributions. In general, the greater the difference between the signal and noise distributions, the better the ability to distinguish non-targets and targets. CPT scores are age and gender standardized T-scores, in which the mean is equal to 50 and the standard deviation is equal to 10. d' is reverse-scored so that higher raw score and T-score values indicate worse performance (i.e., poorer discrimination). Atypical scores are higher than 60 indicating "elevated" to "very elevated" performance.

Outcome measures

Outcome measures
Measure
Active
n=93 Participants
VIZO Glasses- personalized VIZO Glasses: Eyeglasses with personalized peripheral retinal stimuli. Participants were instructed to wear the glasses throughout the day for two months.
Conners' Continuous Performance Test-3 (CPT-3) - Detectability (d') at Baseline and 2 Months Follow up
Baseline
50.03 T-score
Standard Error 0.90
Conners' Continuous Performance Test-3 (CPT-3) - Detectability (d') at Baseline and 2 Months Follow up
End of Study
47.95 T-score
Standard Error 1.06

SECONDARY outcome

Timeframe: Baseline, 2 months

Population: Four participants did not complete the questionnaire.

The Behavior Rating Inventory of Executive Function Adult Version (BRIEF-A) is a standardized measure that captures views of adults' executive functions or self-regulation in their everyday environment. Items are rated on a 3-points Likert scale of 1 ('Never') to 3 ('Often'). The Metacognition Index (MI) of the BRIEF-A reflects the individual's ability to initiate activity and generate problem-solving ideas, to sustain working memory, to plan and organize problem-solving approaches, to monitor success and failure in problem solving, and to organize one's materials and environment. The MI subscale includes 40-items with score ranges between 40 to 120. Higher values represent worse outcome and greater difficulties with executive functions.

Outcome measures

Outcome measures
Measure
Active
n=93 Participants
VIZO Glasses- personalized VIZO Glasses: Eyeglasses with personalized peripheral retinal stimuli. Participants were instructed to wear the glasses throughout the day for two months.
Behavior Rating Inventory of Executive Function Adult Version (BRIEF-A) - Metacognitive Index - at Baseline and 2 Months Follow up
Baseline
79.85 score on a scale (raw scores)
Standard Error 1.75
Behavior Rating Inventory of Executive Function Adult Version (BRIEF-A) - Metacognitive Index - at Baseline and 2 Months Follow up
End of Study
77.76 score on a scale (raw scores)
Standard Error 1.75

Adverse Events

Active

Serious events: 0 serious events
Other events: 64 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Active
n=100 participants at risk
VIZO Glasses- personalized VIZO Glasses: Eyeglasses with personalized peripheral retinal stimuli. Participants were instructed to wear the glasses throughout the day for two months.
General disorders
Headache
36.0%
36/100 • Adverse event data was collected during the two-month intervention period.
All side effects were transient, reported to be mild or moderate, and resolved after the removal of the glasses.
General disorders
Eyestrain
20.0%
20/100 • Adverse event data was collected during the two-month intervention period.
All side effects were transient, reported to be mild or moderate, and resolved after the removal of the glasses.
General disorders
Dizziness
18.0%
18/100 • Adverse event data was collected during the two-month intervention period.
All side effects were transient, reported to be mild or moderate, and resolved after the removal of the glasses.
General disorders
Tiredness
9.0%
9/100 • Adverse event data was collected during the two-month intervention period.
All side effects were transient, reported to be mild or moderate, and resolved after the removal of the glasses.
General disorders
Discomfort
7.0%
7/100 • Adverse event data was collected during the two-month intervention period.
All side effects were transient, reported to be mild or moderate, and resolved after the removal of the glasses.

Additional Information

Yael Richter, PhD

VIZO Specs

Phone: 972-54-7384809

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place